Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.

Ann Hematol · 2025 · PMC11868209 · PMID 39499299

Europe PMC DOI

hedged sentence

0.3700

closest p · 7.4× alpha

0.3700

boldest claim

The sentences

did not reach statistical significancep = 0.37not close (p > 0.1)

Additionally, a longer PFS was noted for those treated with zanubrutinib although it did not reach statistical significance (not reached vs 44.2 months; HR, 0.66; p = 0.37, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.